M. Clemons

917 total citations
24 papers, 551 citations indexed

About

M. Clemons is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, M. Clemons has authored 24 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in M. Clemons's work include Bone health and treatments (9 papers), Cancer Treatment and Pharmacology (7 papers) and Cancer Diagnosis and Treatment (5 papers). M. Clemons is often cited by papers focused on Bone health and treatments (9 papers), Cancer Treatment and Pharmacology (7 papers) and Cancer Diagnosis and Treatment (5 papers). M. Clemons collaborates with scholars based in Canada, United Kingdom and Belgium. M. Clemons's co-authors include Jaco J. Verweij, Claus Kamby, Martin Harris, Q. van Hoesel, Eugenio Donato Di Paola, John Radford, A.T. van Oosterom, J Whittaker, C. Hermans and Jean‐Yves Blay and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

M. Clemons

22 papers receiving 532 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Clemons Canada 8 383 200 179 82 79 24 551
Gopal Ramakrishnan India 6 240 0.6× 99 0.5× 193 1.1× 123 1.5× 191 2.4× 7 598
J Whittaker United States 4 228 0.6× 167 0.8× 90 0.5× 157 1.9× 226 2.9× 8 510
Soeren Daugaard Denmark 7 219 0.6× 303 1.5× 68 0.4× 89 1.1× 81 1.0× 8 717
Gurpreet Lamba United States 8 113 0.3× 104 0.5× 113 0.6× 107 1.3× 103 1.3× 22 464
Bettina Schwarz Germany 14 217 0.6× 105 0.5× 228 1.3× 193 2.4× 37 0.5× 20 756
Andreas Hilbig Germany 16 391 1.0× 130 0.7× 112 0.6× 152 1.9× 16 0.2× 28 756
L Roman Russia 6 288 0.8× 57 0.3× 73 0.4× 123 1.5× 138 1.7× 9 676
Elizabeth Valentine United States 9 314 0.8× 82 0.4× 46 0.3× 81 1.0× 30 0.4× 26 565
G. D’Addario Switzerland 7 318 0.8× 426 2.1× 99 0.6× 129 1.6× 18 0.2× 12 651
Ari J. Rosenberg United States 14 336 0.9× 160 0.8× 56 0.3× 141 1.7× 17 0.2× 69 636

Countries citing papers authored by M. Clemons

Since Specialization
Citations

This map shows the geographic impact of M. Clemons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Clemons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Clemons more than expected).

Fields of papers citing papers by M. Clemons

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Clemons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Clemons. The network helps show where M. Clemons may publish in the future.

Co-authorship network of co-authors of M. Clemons

This figure shows the co-authorship network connecting the top 25 collaborators of M. Clemons. A scholar is included among the top collaborators of M. Clemons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Clemons. M. Clemons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ibrahim, Mohammed, Gregory R. Pond, Tony Ng, et al.. (2025). A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study). npj Breast Cancer. 11(1). 49–49. 2 indexed citations
2.
Awan, Arif, Carol Stober, Gregory R. Pond, et al.. (2024). A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer. Breast Cancer Research and Treatment. 208(3). 523–533. 1 indexed citations
3.
Murshed, Monzur, Mahvash Zakikhani, Iryna Kuchuk, et al.. (2021). Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients. Bone Reports. 15. 101145–101145. 1 indexed citations
4.
5.
6.
7.
Kuchuk, Iryna, et al.. (2012). Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists. Journal of bone oncology. 2(1). 38–46. 16 indexed citations
8.
Bouganim, Nathaniel, George Dranitsaris, Lisa Vandermeer, et al.. (2011). Prospective validation of risk prediction models for acute and delayed chemotherapy-induced nausea and vomiting (CINV).. Journal of Clinical Oncology. 29(15_suppl). 6103–6103. 1 indexed citations
9.
Hilton, John, Lisa Vandermeer, Sean Hopkins, et al.. (2011). A multicenter study assessing 12-weekly intravenous bisphosphonate therapy in women with low-risk bone metastases from breast cancer: The TRIUMPH trial.. Journal of Clinical Oncology. 29(15_suppl). TPS242–TPS242. 1 indexed citations
10.
Fallowfield, Lesley, J.J. Body, Alison Stopeck, et al.. (2011). P4-13-01: Pain Severity and Analgesic Use Associated with Skeletal-Related Events in Patients with Advanced Breast Cancer and Bone Metastases.. Cancer Research. 71(24_Supplement). P4–13. 3 indexed citations
11.
Hilton, John, Lisa Vandermeer, Sean Hopkins, et al.. (2011). OT1-01-02: A Multicentre Study Assessing 12-Weekly Intravenous Bisphosphonate Therapy in Women with Low Risk Bone Metastases from Breast Cancer – The TRIUMPH Trial.. Cancer Research. 71(24_Supplement). OT1–1. 3 indexed citations
12.
13.
Amir, Eitan, et al.. (2009). Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer. Journal of Clinical Pathology. 62(5). 474–476. 7 indexed citations
14.
Lemieux, Julie, M. Clemons, Louise Provencher, et al.. (2009). The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers. Current Oncology. 16(5). 48–57. 10 indexed citations
15.
Chin, Sheray N., et al.. (2008). The prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Journal of Clinical Oncology. 26(15_suppl). 20551–20551. 1 indexed citations
16.
Mackey, John R., M. Clemons, Susan Dent, et al.. (2008). Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group. Current Oncology. 15(1). 24–35. 100 indexed citations
17.
Dranitsaris, George, M. Clemons, Santosh K. Verma, & M. Vincent. (2007). P102 Development of a risk prediction model for neutropenic complications in breast cancer patients receiving adjuvant chemotherapy. The Breast. 16. S41–S42. 1 indexed citations
18.
Clemons, M., et al.. (2004). A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC). Journal of Clinical Oncology. 22(14_suppl). 630–630. 17 indexed citations
19.
20.
Judson, Ian, John Radford, Martin Harris, et al.. (2001). Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma. European Journal of Cancer. 37(7). 870–877. 296 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gopal Ramakrishnan Breakdown of academic impact, for papers by J Whittaker Breakdown of academic impact, for papers by Soeren Daugaard Breakdown of academic impact, for papers by Gurpreet Lamba Breakdown of academic impact, for papers by Bettina Schwarz Breakdown of academic impact, for papers by Andreas Hilbig Breakdown of academic impact, for papers by L Roman Breakdown of academic impact, for papers by Elizabeth Valentine Breakdown of academic impact, for papers by G. D’Addario Breakdown of academic impact, for papers by Ari J. Rosenberg
Rankless by CCL
2026